Drug-eluting stents (DES) would not be used if they did not benefit patients. To that end, vendors conduct clinical studies to show that their product is equal to or better than a previous-generation product or a current competitor’s product.

Medtronic reported that sales of spinal and heart devices helped boostoverall profit and revenue during its first quarter of fiscal year of2009, which ended July 25.

Cardiac Science, a provider of cardiology products, has reported $52.1 million in revenue for the second quarter of 2008, which ended June 30, an increase of 16 percent over the prior year period, despite a lower net income.

Planning and creating the best cath lab for your facility and market requires a wide range of considerations, from current and future business patterns to space design to workflow and communication concerns. A good plan that includes input from all the relevant stakeholders goes a long way toward a successful long-term venture.

Cardiovascular Business invited representatives from the four major stent manufacturers to discuss the challenges and future outlook for drug-eluting stents (DES).

As multifunctional cardiac catheterization labs see new cardiovascular products constantly arriving and old ones getting pushed to the back shelves, administrators need a well-organized storage space, as well as a sophisticated method for integrated inventory management to control costs and revenue.

Defibtech and the Sudden Cardiac Arrest Association (SCAA) have launched an effort to provide automated external defibrillators (AEDs) to communities with critical needs.

St. David’s HealthCare, along with Texas Cardiac Arrhythmia, hasdeveloped the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’sMedical Center in Austin.